Nektar Went From S&P 500 Darling to Reject in 18 Months
The headquarters of Nektar Therapeutics in San Francisco, California.
Photographer: Smith Collection/Gado/Getty ImagesThis article is for subscribers only.
For Nektar Therapeutics, life comes at you fast.
The once high-flying biotech company that rode data and deal speculation to become the best performer in S&P 500 will see its time in the Index come to an end next week. The short stint on one of the most closely watched indexes will have lasted just over 18 months -- a period which saw Nektar shed over 80% of its value following a more than 500% boom.